Salvage of renal transplant with vacuum-assisted thrombectomy of large iliocaval and allograft venous outflow thrombus

Steven D. Kao Martin P. Edwards Stephen T. Kee John M. Moriarty

ABSTRACT
A 47-year-old male with a remote renal transplant due to pediatric glomerulonephritis on oral anticoagulation for symptomatic deep venous thrombosis and pulmonary emboli presented with sudden hip and groin pain. The patient was found to have a spinal epidural hematoma, underwent reversal of anticoagulation, and subsequently developed worsening renal function. Imaging revealed occlusive iliocaval venous thrombosis with extension to the renal allograft. Given risk of epidural hematoma expansion, the patient was deemed high risk for thrombolysis. The AngioVac system was used for single session thrombus removal. The patient’s renal function improved and no focal neurologic sequelae was noted postprocedure. Six-month follow-up showed persistent vessel patency.

Venous thromboembolism has been successfully treated with pharmacologic thrombolysis, pharmacomechanical and mechanical thrombectomy. Aspiration thrombectomy is a particularly attractive option when there is a contraindication to anticoagulation or thrombolytic therapy, such as in the setting of trauma, recent major surgery, hemorrhage, or intracranial mass. The AngioVac aspiration thrombectomy system (AngioDynamics Inc.) has demonstrated utility in the evacuation of venous and right atrial thromboembolus, vegetation, foreign body, and tumor mass (1). The large-bore 22 French (F) device provides suction through a venovenous closed-circuit bypass with in-line filtration of autologous blood and outflow via a separate reperfusion catheter. We report a case of a anticoagulation-associated spinal epidural hematoma in which the AngioVac device was successfully used to perform thrombectomy in a patient with extensive iliocaval thrombus causing renal transplant failure secondary to venous obstruction. There was no neurologic sequelae and renal transplant function was salvaged.

Technique
A 47-year-old male with a history of right iliac fossa renal transplant secondary to pediatric glomerulonephritis presented to an outside hospital with acute onset shortness of breath and posterior right knee pain, with associated erythema and ecchymosis after 6 hours of automobile travel. Imaging revealed deep venous thrombosis (DVT) and pulmonary embolus (PE) for which he was treated with warfarin and discharged home. A week after discharge, the patient experienced acute right hip and groin pain and returned to the outside hospital where magnetic resonance imaging (MRI) of the lumbar spine revealed an L4-S1 epidural hematoma causing severe central canal stenosis and mass effect on the cauda equina (Fig. 1a). The patient’s international normalized ratio (INR) was found to be 2.6. Anticoagulation was immediately reversed with prothrombin complex concentrate and a Gunther-Tulip inferior vena cava (IVC) filter placed to prevent further PE. Shortly thereafter, the patient’s leg swelling and right hip and groin pain worsened and the serum creatinine level rose to 5.8 mg/dL from a baseline of 1.6 mg/dL. Despite patent transplant renal vasculature on duplex ultrasound, creatinine levels continued to rise over the next several days. Urine analysis and bacterial cultures were unrevealing. The patient was transferred to our institution 8 days after re-admission for advancement of care.
Upon arrival, the patient had right lower extremity swelling and pain. The patient otherwise had a normal neurologic exam and denied shortness of breath or chest pain. Ultrasound demonstrated extensive occlusive thrombus throughout the right lower extremity with extension up to the level of the renal transplant venous anastomosis. Lab values were notable for an INR of 1.1 and activated partial thromboplastin time (aPTT) of 23.3, both within normal range. Ferumoxytol contrast-enhanced magnetic resonance venography (MRV) demonstrated a large infrahepatic caval thrombus extending from the IVC filter down into the bilateral common, external and internal iliac veins and nonocclusive thrombus within the transplant renal vein (Fig. 1b, 1c). Thrombolysis was contraindicated due to risk of epidural hematoma expansion. However, given the risk of imminent renal graft loss due to venous outflow occlusion, mechanical thrombectomy using the AngioVac device with administration of tightly controlled short duration intraprocedural anticoagulation was considered the best option. The benefits, risks and alternatives of this off-label use of the AngioVac device were discussed with the patient. The patient understood and consented to the procedure.

Following induction of general anesthesia, a 26 F dry-seal sheath (W.L. Gore) and an 18-F reperfusion catheter were placed to the level of the right atrium and superior vena cava, respectively, in dual right internal jugular vein access sites. Another 26 F dry-seal sheath was
placed into the left common femoral vein. The occluded right femoral vein was cannulated, a 5 F glide catheter was passed into the IVC and exchanged for an 8 F vascular sheath. Venography confirmed absence of flow within the IVC and bilateral iliac veins. Systemic heparinization was carefully initiated with a target activated clotting time of 200–250 seconds. The extracorporeal circuit was brought to the field, prepared and de-aerated. The aspiration catheter was advanced through the left groin dry-seal sheath to the IVC and continuous aspiration was initiated with reperfusion through the right internal jugular (RIJ) access. Extracorporeal bypass flow was increased up to 1.6 L/min. Multiple passes were made through the thrombosed iliocaval system up to the level of the IVC filter with aspiration of large quantities of thrombus (Fig. 2). The circuit was then reconfigured so that aspiration was subsequently performed from the RIJ access. Multiple passes through the iliac veins and IVC were made with extraction of large volume of thrombus. The aspiration catheter was then advanced to the superior aspect of the IVC filter. With continuous AngioVac suction, we proceeded to macerate the infrarenal iliocaval thrombus with dual 16 mm × 4 cm balloons inserted through the bilateral groin sheaths and a 7 F rotational thrombectomy device (Cleaner, Argon Medical) inserted through the right groin sheath. Subsequent low-dose venography confirmed antegrade flow within the iliac veins and IVC with minimal residual thrombus. Given the desire to limit anticoagulation in the setting of an epidural collection, the procedure was completed with a heparinization duration of 1 hour 10 minutes. Access sites were closed with purse string sutures and hemostasis achieved. Vitals were stable throughout the case.

Following the procedure, there was immediate improvement in the patient’s urine output and the serum creatinine level returned to baseline over the next 3 days without the need for hemodialysis. There was no focal neurologic sequelae and therapeutic heparin anticoagulation was reintroduced 10 days following onset of epidural hematoma and 2 days post-procedure. The patient’s leg swelling and pain improved. Follow-up lumbar MRI and pelvic MRV performed 5 days later demonstrated a decrease in size of the epidural collection (Fig. 3a) and patent infrarenal IVC and bilateral iliac veins with some residual thrombus about the IVC filter and in the right lower extremity veins distal to the renal allograft vessels (Fig. 3b). Further rheolytic thrombectomy and IVC filter retrieval were performed on postprocedure day 7. Subsequent intravascular ultrasound examination demonstrated widely patent veins without significant residual thrombus. The patient was discharged on coumadin with weekly clinic visits to maintain a target INR of 2–3. At 3-month clinic follow-up, the patient’s symptoms were improved with mild residual right lower extremity pain and swelling that was well-controlled with leg elevation and compression stockings. At 6-month clinic follow-up, the patient was asymptomatic and renal function was stable. Renal allograft and right lower extremity ultrasound demonstrated widely patent veins without thrombus and anticoagulation was discontinued at that time.

Discussion

Organ or limb threatening venous thrombosis requires rapid diagnosis and management, typically involving anticoagulation with additional thrombolysis or thrombectomy.
When there are contraindications to thrombolysis and/or anticoagulation, therapeutic options become limited. Thrombolysis therapy was contraindicated in this patient given risk of devastating neurologic sequelae (3). Another option, surgical thrombectomy, involving open groin incisions for direct venotomy, with possible adjunctive creation of an arteriovenous fistula and open abdominal incisions, was considered greater risk (4, 5).

Multiple case series have supported the safety and efficacy of the AngioVac device for suction thrombectomy within the right heart and iliocaval system (6, 7). However, there has been no report to date of its use in transplant kidney salvage, particularly in the setting of spinal epidural hemorrhage. The AngioVac was a particularly attractive option in this case with extensive clot burden due to the device’s large caliber, high suction pressure (up to 80 mm Hg) and repletion of autologous intravascular volume through a reperfusion catheter without the need for blood transfusions. The catheter contains a funnel-shaped tip that can be expanded up to 48 F, which allows for apposition of vessel walls and aspiration of large volume mural thrombus. Newer angled canulas now offer additional flexibility for targeted thrombectomy. With suction and reperfusion rates of up to 3 L/min, close monitoring of patient hemodynamics and circuit performance by a trained anesthesiologist and perfusionist is essential. Large volumes of thrombus may be extracted and collected in the filter, which can be replaced intraprocedurally to facilitate en-bloc removal. Combination with other devices such as balloon maceration may aid in thrombus removal.

Normally, an activated clotting time of >300 seconds is targeted for AngioVac thrombectomy (8); however, our goal of 200–250 seconds was established to reduce bleeding risk. Since the patient tolerated the procedure without adverse event, intravenous heparin with bridging to warfarin was initiated 48 hours postprocedurally with close physiologic and biochemical monitoring. It is considered likely that the nidus for his thrombotic progression was due to the IVC filter, hence its removal prior to discharge. Warfarin was chosen for outpatient anticoagulation due to its reversibility in the event of a bleed, a significant factor that is not widely available in more novel agents.

In conclusion, the AngioVac device may be a potentially useful tool in the event of extensive iliocaval thrombosis causing venous obstruction and renal transplant failure.

Conflict of interest disclosure
J.M.M. declares research grant funds from Angiodynamics Inc. The remainder of the authors declare that they have no conflict of interest.

References